Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient, the T cells attack and kill cancer cells that express the antigen, thereby treating the patient. Although ACT holds a great deal of promise, there are still technical drawbacks to be overcome, such as loss of anti-tumor activity due to T cell senescence.
This invention addresses this technical drawback by using T cells that express the transcription factor c-Myb (or a functional variant thereof) at elevated levels as the host for transduction with CARs or TCRs. T cells that exhibit elevated expression of c-Myb display inhibited differentiation, allowing the cells to survive, proliferate and serve in a therapeutic capacity for a longer duration. Since it is believed that these characteristics can increase the effectiveness of ACT, T cells with elevated levels of c-Myb expression are strong candidates for use in ACT.
- Adoptive Cell Therapy (ACT) using chimeric antigen receptors (CARs), or engineered T cell receptors (TCRs)
- Treatment of cancers that express specific cell surface proteins
- Elevated expression of c-Myb in T cells allows them to resist differentiation, thus cells survive and proliferate in greater numbers
- Increased survival and proliferation of T cells allows for a prolonged therapeutic effect
- U.S. Patent Filed: U.S. Patent Application Number PCT/US2016/048435 , Filed 24 Aug 2016
- U.S. Patent Filed: U.S. Patent Application Number 62/209,497, Filed 25 Aug 2015